Artificial intelligence study demonstrates a 52% uplift in patient adherence indicators

Share Article

AllazoHealth, a company that uses artificial intelligence (AI) to help enterprise healthcare companies improve medication adherence, has released a new study demonstrating the impact of AI on patient medication adherence. The new study, published and awarded a gold medal by the Academy of Managed Care Pharmacy (AMCP), demonstrates that AI can effectively identify which patients will achieve greater uplifts in refill rates when a pharmacy-based outreach is added to a phone call.

"Research like this proves that AI makes a positive impact in patient’s lives. It validates the use of AI for adherence across a wide range of enterprise healthcare organizations." commented Clifford Jones, CEO of AllazoHealth.

AllazoHealth, a company that uses artificial intelligence (AI) to help enterprise healthcare companies improve medication adherence and quality outcomes, has released a new study demonstrating the impact of AI on patient adherence indicators. The poster outlining the study was published and awarded a gold medal by the Academy of Managed Care Pharmacy (AMCP). It shows that AI can effectively select which patients will achieve greater uplifts in refill rates by adding a pharmacy-based intervention to a call center intervention.

"Our team was pleased to be awarded a gold ribbon by AMCP, based on our abstract on how AI can uplift adherence indicators," commented Clifford Jones, CEO of AllazoHealth. "Research like this proves that AI makes a positive impact in patient’s lives. It validates the use of AI for adherence across a wide range of enterprise healthcare organizations."

The poster outlines a study showing the effectiveness of using AI to target high-risk patients who would benefit the most from receiving pharmacy-based interventions in addition to call center interventions. Providing a dual intervention approach, both call center-based and pharmacy-based, is more expensive than just utilizing a call center. Therefore, cost efficiency can be improved by reserving the dual intervention approach for patients where it will provide greater uplift in adherence.

High-risk patients who had a prescription fill due or past-due were selected for medication adherence interventions by the AI. Patients who were predicted to benefit from dual interventions, and then received the interventions, were 52% more likely to refill their prescriptions within 14 days than other groups.

The full poster is available for download at
https://allazohealth.com/wp-content/uploads/AllazoHealth-AMCP-Poster.pdf

About AllazoHealth

AllazoHealth uses artificial intelligence to make a positive impact on individual patient behavior. We optimize medication adherence and quality outcomes for pharmaceutical companies, payers, and pharmacies. Our AI engine targets individual patients with the right intervention, the right content, at the right time.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

William Grambley
AllazoHealth
+1 774-219-1336
Email >
@allazohealth
Follow >
Visit website